Short-Chain Fatty Acids in Chronic Kidney Disease: Focus on Inflammation and Oxidative Stress Regulation

Chronic Kidney Disease (CKD) is a debilitating disease associated with several secondary complications that increase comorbidity and mortality. In patients with CKD, there is a significant qualitative and quantitative alteration in the gut microbiota, which, consequently, also leads to reduced production of beneficial bacterial metabolites, such as short-chain fatty acids. Evidence supports the beneficial effects of short-chain fatty acids in modulating inflammation and oxidative stress, which are implicated in CKD pathogenesis and progression. Therefore, this review will provide an overview of the current knowledge, based on pre-clinical and clinical evidence, on the effect of SCFAs on CKD-associated inflammation and oxidative stress.

Automated summary

This review provides an overview of the effect of short-chain fatty acids (SCFAs) on CKD-associated inflammation and oxidative stress, based on pre-clinical and clinical evidence. In patients with chronic kidney disease (CKD), there is a significant alteration in the gut microbiota, resulting in reduced production of beneficial bacterial metabolites. However, SCFAs have been shown to have beneficial effects in modulating inflammation and oxidative stress in CKD.